CrowdStrike Partners With Australia's AARNet to Thwart Cyber-attacks in Research and Learning Institutions
Utilizing real-time attack indicators, threat intelligence, and enriched telemetry from across the enterprise, the CrowdStrike Falcon platform offers hyper-accurate detections. It also enables automated protection and remediation, elite threat hunting, and prioritized observability of vulnerabilities.
Australia's research and learning institutions stand to leverage the AI-powered solution to safeguard their system against any potential cyber-attacks. Powered by CrowdStrike's AI native platform and elite cyber expertise, the solution provides sector-specific services for thwarting potential attacks. The integration comes when sophisticated cyber attackers constantly target Australia's research and education sector.
According to CrowdStrike Vice President Jon Fox, Falcon Complete Next Gen sets the standard for managed detection and response (MDR). Additionally, it is tailored to enhance and accelerate security operation center initiatives in collaboration with innovative service partners like AARNet. The executive expects the solution to be a true force multiplier in helping research cybersecurity teams combat cyber attacks.
AARNet is Australia's national research and education network provider, delivering high-performance telecommunications, cybersecurity, and collaboration services for the country's research, education, and innovation sectors. Owned by Australian universities and CSIRO, AARNet has connected knowledge institutions for over 30 years, enabling global data-intensive science and large-scale international collaboration.
CrowdStrike Holdings, Inc. provides cloud-based cybersecurity solutions globally, protecting endpoints, cloud workloads, identity, and data through a SaaS subscription model. Its Falcon platform offers threat intelligence, identity protection, security automation, vulnerability management, and AI-powered workflow solutions, ensuring comprehensive cyber defense for businesses.
While we acknowledge the potential of Crowdstrike Holdings Inc. (NASDAQ:CRWD) as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than CRWD and that has 100x upside potential, check out our report about the cheapest AI stock.
READ NEXT: and.
Disclosure: None.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
32 minutes ago
- Yahoo
ASX Growth Companies With High Insider Ownership In July 2025
As the ASX 200 begins the new financial year on a flat note, with sectors like Utilities and IT showing modest gains, investors are keenly observing market movements to identify promising opportunities. In this environment, growth companies with high insider ownership often stand out as they can signal strong confidence from those who know the business best, potentially offering resilience and strategic advantage amidst fluctuating market conditions. Name Insider Ownership Earnings Growth Titomic (ASX:TTT) 11.2% 77.2% Newfield Resources (ASX:NWF) 31.5% 72.1% Image Resources (ASX:IMA) 22.3% 79.9% Fenix Resources (ASX:FEX) 21.1% 53.4% Echo IQ (ASX:EIQ) 18% 51.4% Cyclopharm (ASX:CYC) 11.3% 97.8% Brightstar Resources (ASX:BTR) 11.6% 106.7% AVA Risk Group (ASX:AVA) 15.4% 108.2% Alfabs Australia (ASX:AAL) 10.8% 41.3% Adveritas (ASX:AV1) 19.9% 88.8% Click here to see the full list of 94 stocks from our Fast Growing ASX Companies With High Insider Ownership screener. We'll examine a selection from our screener results. Simply Wall St Growth Rating: ★★★★★☆ Overview: Ltd is an online retailer based in Australia with a market capitalization of A$384.35 million. Operations: The company generates revenue through its operations in Australia, with A$309.36 million from Kogan Parent and A$9.96 million from Mighty Ape, as well as in New Zealand, earning A$40.02 million from Kogan Parent and A$124.88 million from Mighty Ape. Insider Ownership: 20.8% is poised for significant earnings growth, forecasted at 34.5% annually, outpacing the Australian market's 10.9%. Despite a dip in profit margins to 0.4% from last year's 1.4%, the company trades at a substantial discount of 63.4% below its estimated fair value, presenting potential value opportunities. Recent executive changes include Belinda Cleminson's appointment as Company Secretary, enhancing corporate governance with her extensive experience in listed companies. Take a closer look at potential here in our earnings growth report. Our comprehensive valuation report raises the possibility that is priced lower than what may be justified by its financials. Simply Wall St Growth Rating: ★★★★★★ Overview: Meeka Metals Limited focuses on the exploration and development of gold properties in Western Australia, with a market cap of A$422.78 million. Operations: Meeka Metals Limited's revenue segments are currently not specified in the provided text. Insider Ownership: 12% Meeka Metals is set for strong growth, with earnings forecasted to rise 54.14% annually and revenue expected to grow at 56.1% per year, significantly outpacing the Australian market. Despite generating less than US$1 million in revenue (A$329K), it trades at a 28.6% discount to its estimated fair value. A recent A$60 million equity offering supports expansion efforts, while high insider ownership aligns management interests with shareholders despite no recent insider trading activity noted. Get an in-depth perspective on Meeka Metals' performance by reading our analyst estimates report here. Insights from our recent valuation report point to the potential undervaluation of Meeka Metals shares in the market. Simply Wall St Growth Rating: ★★★★★☆ Overview: PYC Therapeutics Limited is an Australian drug-development company focused on discovering and developing novel RNA therapeutics for genetic diseases, with a market capitalization of A$755.32 million. Operations: The company generates revenue of A$24.99 million from its activities in the discovery and development of novel RNA therapeutics for genetic diseases. Insider Ownership: 35.9% PYC Therapeutics is poised for growth, with earnings expected to increase by 24.3% annually and become profitable within three years, outperforming the market. Despite recent shareholder dilution, it trades at a significant discount to its estimated fair value. Insider ownership remains high, aligning management interests with shareholders. Recent developments include dosing in a Phase 1a trial of PYC-003, indicating progress in their clinical pipeline and potential future revenue catalysts despite slower revenue growth forecasts of 12.6% annually. Unlock comprehensive insights into our analysis of PYC Therapeutics stock in this growth report. The analysis detailed in our PYC Therapeutics valuation report hints at an inflated share price compared to its estimated value. Take a closer look at our Fast Growing ASX Companies With High Insider Ownership list of 94 companies by clicking here. Seeking Other Investments? Trump's oil boom is here — pipelines are primed to profit. Discover the 22 US stocks riding the wave. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years. Companies discussed in this article include ASX:KGN ASX:MEK and ASX:PYC. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@
Yahoo
an hour ago
- Yahoo
Earnings Estimates Rising for Micron (MU): Will It Gain?
Micron (MU) could be a solid choice for investors given the company's remarkably improving earnings outlook. While the stock has been a strong performer lately, this trend might continue since analysts are still raising their earnings estimates for the company. The upward trend in estimate revisions for this chipmaker reflects growing optimism of analysts on its earnings prospects, which should get reflected in its stock price. After all, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements. This insight is at the core of our stock rating tool -- the Zacks Rank. The five-grade Zacks Rank system, which ranges from a Zacks Rank #1 (Strong Buy) to a Zacks Rank #5 (Strong Sell), has an impressive externally-audited track record of outperformance, with Zacks #1 Ranked stocks generating an average annual return of +25% since 2008. For Micron, there has been strong agreement among the covering analysts in raising earnings estimates, which has helped push consensus estimates considerably higher for the next quarter and full year. The chart below shows the evolution of forward 12-month Zacks Consensus EPS estimate: The company is expected to earn $2.51 per share for the current quarter, which represents a year-over-year change of +112.71%. Over the last 30 days, the Zacks Consensus Estimate for Micron has increased 23.45% because six estimates have moved higher compared to no negative revisions. For the full year, the company is expected to earn $7.77 per share, representing a year-over-year change of +497.69%. There has been an encouraging trend in estimate revisions for the current year as well. Over the past month, eight estimates have moved up for Micron versus no negative revisions. This has pushed the consensus estimate 11.22% higher. The promising estimate revisions have helped Micron earn a Zacks Rank #2 (Buy). The Zacks Rank is a tried-and-tested rating tool that helps investors effectively harness the power of earnings estimate revisions and make the right investment decision. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Our research shows that stocks with Zacks Rank #1 (Strong Buy) and 2 (Buy) significantly outperform the S&P 500. Investors have been betting on Micron because of its solid estimate revisions, as evident from the stock's 25.5% gain over the past four weeks. As its earnings growth prospects might push the stock higher, you may consider adding it to your portfolio right away. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Micron Technology, Inc. (MU) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research
Yahoo
an hour ago
- Yahoo
Castleford's Horne given six-match suspension
Liam Horne had been ever-present for Castleford Tigers in Super League this season [ Castleford Tigers hooker Liam Horne has been given a six-match suspension and fined after being found guilty of making unnecessary contact with a player who is injured or maybe injured. The 27-year-old committed the offence in Saturday's Super League defeat by Wigan Warriors. Advertisement Horne, who pleaded not guilty, will now be unavailable until the trip to Catalans Dragons on Saturday, 23 August. He will also have 36 penalty points added to his disciplinary record. Meanwhile, Hull KR forward Rhyse Martin, 32, was found not guilty of the same offence in his side's win over Wakefield Trinity on Friday. The Australian did plead guilty to a separate charge of head contact and was given one penalty point.
